表达拉沙病毒核蛋白的重组改良安卡拉痘苗疫苗在豚鼠模型中防止疾病进展
本研究基于表达拉沙病毒核蛋白的重组改良安卡拉痘苗(MVALassaNP),在小鼠中评价免疫原性、在豚鼠中评价单剂或初免/加强方案的效力。ELISA与ELISpot证实体液与T细胞免疫,初免/加强应答显著高于单剂(P < 0.0001);豚鼠攻毒后,对照组全部出现临床体征、体重下降与体温升高,而MVALassaNP接种组未见临床体征、发热或体重下降,表明单剂与初免/加强均能防止疾病进展。
要点
- MVALassaNP单剂或初免/加强均诱导小鼠体液与T细胞免疫。
- 初免/加强的免疫应答显著高于单剂(P < 0.0001)。
- 豚鼠攻毒后接种组未见临床体征、发热或体重下降。
核心结论
- MVALassaNP候选疫苗可诱导免疫应答、对拉沙病毒病显示效力,适合进一步开展临床前与临床开发。
研究设计与样本
- 研究在 mice 中评价 MVALassaNP 的免疫原性,在豚鼠中评价其效力,比较初免/加强与单剂接种方案。
主要发现
- ELISA 和 ELISpot 证实初免及初免/加强后均产生体液和 T 细胞免疫,初免/加强应答较单剂显著增加(P < 0.0001)。
- 豚鼠攻毒后,接受对照 MVA 疫苗的动物均出现临床体征、体重下降和体温升高。
- MVALassaNP 接种动物未见临床体征、发热或体重下降,单剂与初免/加强均防止疾病进展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lassa fever remains the most imported viral haemorrhagic fever in Europe and is responsible for 5000 deaths per year throughout Western Africa. There is no vaccine and treatment is often ineffective. We have developed a vaccine based on modified Vaccinia Ankara expressing the nucleoprotein from Lassa virus (MVALassaNP). This study investigated the immunogenicity (in mice) and efficacy (in guinea pigs) of the MVALassaNP vaccine as a prime/boost or single vaccination regime. ELISA and ELISpot assays confirmed humoral and T-cell immunity following both a prime and prime/boost vaccination, with the prime/boost regime producing a statistically increased response compared to a prime only vaccine (P < 0.0001). The vaccine offered protection in guinea pigs against disease manifestations after challenge with virulent Lassa virus. Clinical signs, weight loss and temperature increases were observed in all animals receiving a control MVA vaccine, after challenge with Lassa virus. In contrast, no clinical signs, fever or weight loss were observed in any of the MVALassaNP vaccinated animals demonstrating that both a single immunisation, and prime/boost regime confer protection against disease progression. In conclusion, the MVALassaNP vaccine candidate elicits an immune response, demonstrates efficacy against Lassa virus disease and is suitable for further preclinical and clinical development.
引用
- Kennedy EM, Dowall SD, Salguero FJ, et al. A vaccine based on recombinant modified Vaccinia Ankara containing the nucleoprotein from Lassa virus protects against disease progression in a guinea pig model. Vaccine. 2019. PMID: 31331770. doi:10.1016/j.vaccine.2019.07.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。